Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
|ClinicalTrials.gov Identifier: NCT00899873|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of cells in the laboratory from patients with cancer may help identify biomarkers related to cancer. It may also help doctors learn how patients respond to treatment.
PURPOSE: This laboratory study is analyzing samples of cells from patients with chronic lymphocytic leukemia who were treated on clinical trial ECOG-2997.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: cytogenetic analysis Other: flow cytometry Other: fluorescence activated cell sorting Other: immunoenzyme technique Other: laboratory biomarker analysis|
- To analyze the expression of a variety of informative molecules using a unique high-resolution flow cytometric immunophenotyping technology in samples from patients with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.
OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70, phospho-Syk, phospho-GSK-3β, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1, phospho-ReIA, IkappaBα, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker signals are amplified using enzymatic amplification staining to obtain high resolution detection of cell-surface markers on leukemic cells. Biomarker expression levels are measured using fluorescence activated cell sorting analysis. Relationships between clinical outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution immunophenotyping will also be assessed.
|Study Type :||Observational|
|Actual Enrollment :||225 participants|
|Official Title:||Proposed Study of CLL Samples|
|Actual Study Start Date :||April 17, 2012|
|Actual Primary Completion Date :||July 17, 2012|
|Actual Study Completion Date :||July 17, 2012|
- Correlation of biomarker analysis and correlation with outcome response [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899873
|Study Chair:||David Kaplan, MD, PhD||University Hospitals Seidman Cancer Center|